Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2025-04-17 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
关于召开2024年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of shareholders for the company 和元生物技术（上海）股份有限公司. It includes the date, voting methods, meeting agenda items, and instructions for shareholders to attend and vote. The document does not contain the actual annual report or financial statements but rather the announcement and procedural details for the AGM. The document length is 4024 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2025-04-17 Chinese
第三届董事会第十九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 19th meeting of the 3rd Board of Directors of Heyuan Biotech (Shanghai) Co., Ltd. It includes approvals of various reports such as the 2024 Annual Report and its summary, the 2024 General Manager's Work Report, the 2024 Board Work Report, the 2024 Independent Directors' Reports, the 2024 Internal Control Evaluation Report, the 2024 Financial Final Report, and others. It also mentions that these reports are published on the Shanghai Stock Exchange website and that the resolutions will be submitted to the shareholders' meeting for approval. The document is not the reports themselves but a formal board meeting resolution announcement regarding these reports and other corporate governance matters. The document length is 6933 characters, which is relatively short for full reports but appropriate for a board meeting resolution announcement. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official regulatory announcement of board resolutions and report approvals, not the reports themselves or their full content.
2025-04-17 Chinese
关于召开2024年度暨2025年第一季度业绩说明会的公告
Call Transcript Classification · 95% confidence The document is an announcement about the scheduling and details of an upcoming earnings performance explanation meeting (业绩说明会) for the 2024 annual and 2025 first quarter results. It includes the meeting time, location, participation method, and contact information. It references that the 2024 annual report and 2025 Q1 report have or will be disclosed separately. The document does not contain actual financial data or detailed financial statements but is an invitation and information about the earnings call event. Therefore, it is best classified as a Call Transcript (CT) type document, specifically an announcement of an earnings call or performance explanation meeting, which fits the Call Transcript category better than others. The document length is short and it is not the report itself, so it is not an Annual Report or Interim Report. Confidence is high due to clear keywords and context.
2025-04-17 Chinese
董事会关于独立董事独立性情况的专项意见
Governance Information Classification · 95% confidence The document is a statement from the company's board regarding the independence of its independent directors. It discusses the self-assessment and evaluation of the independent directors' independence in accordance with relevant regulatory rules and company bylaws. There is no financial data, no mention of financial results, no voting results, no management changes, no legal proceedings, or other report types. The document is a governance-related statement focusing on board composition and director independence. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-04-17 Chinese
关于提请股东大会授权董事会办理以简易程序向特定对象发行股票相关事宜的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the board of directors of a company regarding a proposal to the shareholders' meeting to authorize the board to handle a simplified procedure for a private placement of shares to specific investors. It details the terms, conditions, authorization period, and procedural aspects of the proposed share issuance. The document does not contain actual financial statements or results but is a formal notice about a capital raising plan requiring shareholder approval. It is not a full financial report, earnings release, or regulatory certification. The content fits the category of a Capital/Financing Update, as it concerns a financing activity and capital structure change announcement.
2025-04-17 Chinese
关于股份回购实施结果的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement about the implementation results of a share repurchase program by the company 和元生物技术（上海）股份有限公司. It includes specifics such as the number of shares repurchased, the price range, the total amount spent, the purpose of the repurchase, and the handling of the repurchased shares. It references prior announcements and approvals related to the repurchase plan. The content focuses on the completion and results of the share buyback, which aligns with the category of a report on transactions in the company's own shares. The document length is 2781 characters, which is sufficient to provide substantive details rather than just a brief announcement or a report publication notice. Therefore, the appropriate classification is Transaction in Own Shares (POS).
2025-04-11 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.